Lowering of brachial pulse pressure in 9379 hypertensives with type 2 diabetes and reduction of cardiovascular events

Blood Pressure

Volumn 17, Issue 1, 2008, Pages 26-33

  Tropeano, Anne Isabelle ^a,b   Katsahian, Sandrine ^c   Molle, Daniel ^d   Grimaldi, André ^e   Laurent, Stéphane ^a  

^a HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

^b HENRI MONDOR HOSPITAL   (France)

^c SAINT LOUIS HOSPITAL   (France)

^d Therval Medical   (France)

^e PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

Author keywords

Arterial stiffness; Cardiovascular events; Combination therapy; Predictive value; Pulse pressure; Type 2 diabetes

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIDIABETIC AGENT; ANTIHYPERTENSIVE AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM ANTAGONIST; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; GLYCOSYLATED HEMOGLOBIN; INDAPAMIDE PLUS PERINDOPRIL; INSULIN; METFORMIN; SULFANILAMIDE; SULFONYLUREA DERIVATIVE;

ADULT; AGED; ARTICLE; BRACHIAL ARTERY; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL TRIAL; COHORT ANALYSIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIABETIC HYPERTENSION; DRUG DOSE COMPARISON; FEMALE; FOLLOW UP; HEART FAILURE; HEART INFARCTION; HEMOGLOBIN BLOOD LEVEL; HUMAN; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; NON INSULIN DEPENDENT DIABETES MELLITUS; OUTCOME ASSESSMENT; PATIENT CARE; PREDICTION; PRIORITY JOURNAL; PULSE PRESSURE; RISK REDUCTION; STROKE; TREATMENT DURATION;

ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; BRACHIAL ARTERY; CARDIOVASCULAR DISEASES; COHORT STUDIES; DIABETES MELLITUS, TYPE 2; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG COMBINATIONS; FEMALE; FOLLOW-UP STUDIES; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPERTENSION; INDAPAMIDE; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PERINDOPRIL; PROSPECTIVE STUDIES; RISK FACTORS; TREATMENT OUTCOME;

EID: 45949112582     PISSN: 08037051     EISSN: 16511999     Source Type: Journal    
DOI: 10.1080/08037050701786613     Document Type: Article

References (32)

1. Darne, B., Girerd, X., Safar, M., Cambien, F. and Guize, L. (1989) Pulsatile versus steady component of blood pressure: A cross-sectional analysis of a prospective analysis of cardiovascular mortality. Hypertension, 13, pp. 392-400.
2. Benetos, A., Safar, M., Rudnichi, A., Smulyan, H., Richard, J. L. Ducimetiere, P. et al. (1997) Pulse pressure: A predictor of long-term cardiovascular mortality in a French male population. Hypertension, 30, pp. 1410-1415.
3. Franklin, S. S., Gustin, W 4th., Wong, N. D., Larson, M. G., Weber, M. A. Kannel, W. B. et al. (1997) Hemodynamic patterns of age-related changes in blood pressure. The Framingham Heart Study. Circulation, 96, pp. 308-315.
4. Cockcroft, J. R., Wilkinson, I. B., Evans, M., McEwan, P., Peters, J. R. Davies, S. et al. (2005) Pulse pressure predicts cardiovascular risk in patients with type 2 diabetes mellitus. Am J Hypertens, 18, pp. 1463-1467.
5. Laurent, S., Cockkroft, J., Van Bortel, L., Boutouyrie, P., Giannattasio, C. Hayoz, D. et al. (2006) Expert consensus document on arterial stiffness: Methodological issues and clinical applications. Eur Heart J, 27, pp. 2588-2605.
6. Blacher, J., Staessen, J. A., Girerd, X., Gasowski, J., Thijs, L. Liu, L. et al. (2000) Pulse pressure not mean pressure determines cardiovascular risk in older hypertensive patients. Arch Intern Med, 160, pp. 1085-1089.
7. Schram, M. T., Henry, R. M., van Dijk, R. A., Kostense, P. J., Dekker, J. M. Nijpels, G. et al. (2004) Increased central artery stiffness in impaired glucose metabolism and type 2 diabetes: The Hoorn Study. Hypertension, 43, pp. 176-181.
8. Tropeano, A. I., Boutouyrie, P., Pannier, B., Joannides, R., Balkestein, E. Katsahian, S. et al. (2006) Pressure-independent reduction in carotid artery stiffness after long-term ACE inhibition in diabetic hypertensives. Hypertension, 48, pp. 80-86.
9. Asmar, R. G., London, G. M., O'Rourke, M. E. and Safar ME, REASON Project Coordinators and Investigators (2001) Improvement in blood pressure, arterial stiffness and wave reflections with a very-low-dose perindopril/indapamide combination in hypertensive patient: A comparison with atenolol. Hypertension, 38, pp. 922-926.
10. Heart outcomes prevention evaluation study investigators (2000) Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: Results of the HOPE and MICRO-HOPE substudy. Lancet, 355, pp. 253-259.
11. Mogensen, C. E., Viberti, G., Halimi, S., Ritz, E., Ruilope, L. Jermendy, G. et al. (2003) Effect of low-dose perindopril/indapamide on albuminuria in diabetes preterax in albuminuria regression: PREMIER. Hypertension, 41, pp. 1063-1071.
12. Davidian, M. and Giltinan, D. M. (1995) Nonlinear models for repeated measurement data: Monographs on statistics and applied probability. p. 359. Chapman & Hall, Boca Raton, FL
13. Pinheiro, J. and Bates, D. (2000) Mixed-effects models in S and S-Plus, Statistics and Computing Series, Springer-Verlag, New York
14. Schwartz, G. (1978) Estimating the dimension of a model. Ann Stat, 6, pp. 461-464.
15. Boutouyrie, P., Bussy, C., Lacolley, P., Girerd, X., Laloux, B. and Laurent, S. (1999) Association between local pulse pressure, mean blood pressure and arterial remodeling. Circulation, 100, pp. 1387-1393.
16. Boutouyrie, P., Bussy, C., Hayoz, D., Hengstler, J., Dartois, N. Laloux, B. et al. (2000) Local pulse pressure and regression of arterial wall hypertrophy during long-term antihypertensive treatment. Circulation, 101, pp. 2601-2606.
17. Tropeano, A. I., Boutouyrie, P., Katsahian, S., Laloux, B. and Laurent, S. (2004) Glucose level is a major determinant of carotid intima-media thickness in patients with hypertension and hyperglycemia. J Hypertens, 22, pp. 2153-2160.
18. Laurent, S., Kingwell, B., Bank, A., Weber, M. and Struijker-Boudier, H. (2002) Clinical applications of arterial stiffness: Therapeutics and pharmacology. Am J Hypertens, 15, pp. 453-458.
19. Laurent, S. (2003) Very-low-dose combination of perindopril and indapamide: Efficacy on blood pressure and target-organ damage. J Hypertens, 21, pp. S11-S18.
20. Safar, M., Van Bortel, L. and Struijker-Boudier, H. (1997) Resistance and conduit arteries following converting enzyme inhibition in hypertension. J Vascular Res, 81, pp. 34-67.
21. Mourad, J. J., Waeber, B., Zannad, F., Laville, M., Duru, G., Andrejak, M. and investigators of the STRATHE trial (2004) Comparison of different therapeutic strategies in hypertension: A low-dose combination of perindopril/indapamide versus a sequential monotherapy or a stepped-care approach. J Hypertens, 22, pp. 2379-2386.
22. Julius, S., Kjeldsen, S. E., Weber, M., Brunner, H. R., Ekman, S., Hansson, L. VALUE trial group et al. (2004) Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: The VALUE randomised trial. Lancet, 363, pp. 2022-2031.
23. Williams, B., Lacy, P. S., Thom, S. M., Cruickshank, K., Stanton, A. Collier, D. et al. (2006) Differential impact of blood pressure-lowering drugs on central aortic pressure and clinical outcomes. Principal results of the conduit artery function evaluation (CAFE) study. The CAFE investigators, for the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT) investigators. Circulation, 113, pp. 1213-1225.
24. Banes, A. J., Tsuzaki, M., Yamamoto, J., Fisher, T., Brigman, B. Brown, T. et al. (1995) Mechanoreception at the cellular level: The detection, interpretation, and diversity of responses to mechanical signals. Biochem Cell Biol, 73, pp. 349-365.
25. Eckel, R. H., Wassef, M., Chait, A., Sobel, B., Barrett, E. King, G. et al. (2002) Prevention Conference VI: Diabetes and Cardiovascular Disease. Writing Group II: Pathogenesis of atherosclerosis in diabetes. Circulation, 105, pp. e138-e143.
26. Balkau, B., Bertrais, S. and Ducimetiere, P. (1999) Is there a glycemic threshold for mortality risk?. Diabetes care, 22, pp. 696-69922.
27. Fox, K. M. and EURopean trial On reduction of cardiac events with Perindopril in stable coronary Artery disease Investigators (2003) Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: Randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study). Lancet, 362, pp. 782-788.
28. Laurent, S. (2005) Evidence for benefits of perindopril in hypertension and its complications. Am J Hypertens, 18, pp. 155S-162S.
29. Sowers, J. R., Epstein, M. and Frohlich, E. D. (2001) Diabetes, hypertension, and cardiovascular disease: An update. Hypertension, 37, pp. 1053-1059.
30. Marx, N., Duez, H., Fruchart, J. C. and Staels, B. (2004) Peroxisome proliferator-activated receptors and atherogenesis: Regulators of gene expression in vascular cells. Circ Res, 1494, pp. 1168-1178.
31. Patel, A. and ADVANCE Collaborative Group (2007) Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): A randomised controlled trial. Lancet, 370, pp. 829-840.
32. Vinik, A. I., Maser, R. E., Mitchell, B. D. and Freeman, R. (2003) Diabetic autonomic neuropathy. Diabetes Care, 26, pp. 1553-1579.